INTRODUCTION
• Overactive bladder (OAB) is a condition that is highly prevalent in the population 1 • Patients with OAB tend to be older, with various comorbidities such as cardiovascular disease, arthritis, depression and chronic obstructive pulmonary disease (COPD). Published literature shows an association between OAB and events such as falls and fractures, urinary tract and skin infections, sleep disturbances and depression 2 • Anticholinergic drugs (ACHDs) are an established therapy for treating symptoms of OAB; however, they are known to have a poor tolerability profile 3 • Fifty per cent of patients discontinue an ACHD within six months of treatment initiation, the majority within the first two months. Despite these high discontinuation rates, patients cycle through multiple ACHDs 4 • There is limited evidence assessing the impact on healthcare burden in secondary care of patients with OAB who are refractory to ACHDs
OBJECTIVE
• The objective of the study was to analyse the variation in healthcare burden in secondary care of patients with OAB who cycle through multiple ACHDs
METHODS
• A retrospective observational study was conducted in a secondary care setting to examine the relationship between healthcare burden and the number of prior ACHDs (used as a proxy for patients whose OAB [excluding neurogenic disorders] is inadequately managed) • Data were extracted from the Hospital Episode Statistics (HES) database and 3,059 GP practices on patients with a diagnosis of OAB, or any of the symptoms of OAB (frequency, urgency, incontinence or nocturia), and with at least one prescription for an ACHD between April 2007 and March 2013. The index date was defined as the first ACHD prescription date during the study period • The inclusion criteria were: adult patients with at least 12 months of prior medical history data available post the index date and at least 12 months with no ACHD prescription prior to the index date • Each person acted as their own control from 1 ACHD to 3+ ACHDs (for utilisation comparisons) • Patients were followed from their first ACHD prescription date during the study period until their transfer-out date, death or end of study (September 2013) • For 1 ACHD, patients contributed person-time until they were prescribed a second ACHD; for 2 ACHDs, patients contributed persontime until they were prescribed a third ACHD; for 3+ ACHDs, persontime included time from the prescription of a third ACHD Statistical methods • Data were analysed according to the number of ACHDs prescribed during follow-up • Treatment activity and cost burden were analysed. Calculations were performed following the initiation of the second and third ACHD in primary care and compared with the same cohort at the point at which they had received the first ACHD • Additional activity and cost burden associated with comorbid conditions prevalent among OAB patients (including cardiovascular disease, renal failure, diabetes, anxiety and depression) and injuries such as falls and fractures were also analysed • All costs were calculated by applying National Health Service (NHS) tariff prices to the treatment activity
RESULTS
• Overall, the number of patients identified was 13,117, with 34% (4,414) receiving a second ACHD and 12% (1,555) receiving three or more ACHDs during follow-up ( • There was a 41% increase in hospitalisations across all settings between the first and third ACHD, from 56.0 to 78.8 interactions per 100 population ( 
LIMITATIONS
• No adjustment was made for confounding factors; eg, differences in the availability of OAB treatments over the course of the study period • People progressing to 3+ ACHDs may have more severe or complicated disease and progression may not be due to inadequate management
